NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Jade Biosciences, Inc. (JBIO) Stock Analysis

Jade Biosciences, Inc. (JBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JBIO

$19.90

+$0.05 (+0.25%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JBIO with… →

JBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$19.86
Previous Close
$19.85
Day's Range
19.70–20.35
52-Week Range
6.91–28.00
Volume
605.00K
Valuation
Market Cap
$1.27B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$127.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.60M
1-Year Return
+155.78%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+28.97%
2025−82.93%
2024−88.29%
2023−22.76%
2022+148.52%
2021 (partial year)−48.36%

As of September 4, 2026.

JBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricJBIOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jade Biosciences, Inc. (JBIO) at $1.27B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 55 employees.

The most recent close on file for JBIO is $19.90, dated September 4, 2026. That is +$0.05 (+0.25%) against the previous close. Over the past 52 weeks the price has ranged from $6.91 to $28.00. The latest close sits 187.99% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $127.41M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.07.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +155.78%. Across 5 years the annualized return works out at −50.68%. Annualized volatility over the trailing 5 years is 101.1%.

Growth & Income

The record shows no dividend for JBIO.

So far in 2026 the price is +28.97%. Across the complete calendar years on file, 2022 returned +148.52% and 2024 returned −88.29%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Jade Biosciences, Inc. (JBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jade Biosciences, Inc. JBIO $1.27B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Jade Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Visit website →